EcoDrugPlus

Leukotriene B4 Receptor 1-Like

Ensembl ID : ENSSLDG00000005815
Gene Symbol: LOC111661738
3 Cross references
142 Possible Orthologues:

Leukotriene B4 Receptor 1-Like

Ensembl ID : ENSSLDG00000005800
Gene Symbol: LOC111661739
3 Cross references
157 Possible Orthologues:

Lysine Demethylase 1a

Ensembl ID : ENSSLDG00000019581
Gene Symbol: KDM1A
3 Cross references
212 Possible Orthologues:

Lysyl Oxidase Homolog 2a-Like

Ensembl ID : ENSSLDG00000019052
Gene Symbol: LOC111670928
3 Cross references
208 Possible Orthologues:

Lysyl Oxidase Homolog 2b-Like

Ensembl ID : ENSSLDG00000012869
Gene Symbol: LOC111647954
3 Cross references
213 Possible Orthologues:

Macrophage Colony-Stimulating Factor 1 Receptor 2-Like

Ensembl ID : ENSSLDG00000021856
Gene Symbol: LOC111671143
2 Cross references
203 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSSLDG00000000566
Gene Symbol: MIF
3 Cross references
229 Possible Orthologues:

Macrophage Stimulating 1 Receptor

Ensembl ID : ENSSLDG00000009798
Gene Symbol: MST1R
3 Cross references
193 Possible Orthologues:

Macrophage-Stimulating Protein Receptor-Like

Ensembl ID : ENSSLDG00000002527
Gene Symbol: LOC111657867
2 Cross references
188 Possible Orthologues:

Mast/stem Cell Growth Factor Receptor Kita-Like

Ensembl ID : ENSSLDG00000024132
Gene Symbol: LOC111664577
3 Cross references
200 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSSLDG00000015649
Gene Symbol: MMP2
3 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSSLDG00000003000
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).